A new trading day began on Friday, with Travere Therapeutics Inc (NASDAQ: TVTX) stock price down -20.57% from the previous day of trading, before settling in for the closing price of $21.15. TVTX’s price has ranged from $6.01 to $25.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 13.83%. Meanwhile, its annual earnings per share averaged 73.49%. With a float of $87.46 million, this company’s outstanding shares have now reached $88.79 million.
Let’s determine the extent of company efficiency that accounts for 385 employees. In terms of profitability, gross margin is 92.23%, operating margin of -81.81%, and the pretax margin is -82.6%.
Travere Therapeutics Inc (TVTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.51%, while institutional ownership is 112.62%. The most recent insider transaction that took place on May 05 ’25, was worth 37,553. In this transaction CHIEF FINANCIAL OFFICER of this company sold 1,784 shares at a rate of $21.05, taking the stock ownership to the 93,126 shares. Before that another transaction happened on May 05 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 18,924 for $21.05, making the entire transaction worth $398,350. This insider now owns 419,173 shares in total.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 73.49% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Here are Travere Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.80, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach 0.81 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 2.42 million, which is a jump from its year-to-date volume of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 42.20%. Additionally, its Average True Range was 1.37.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 31.42%, which indicates a significant increase from 4.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.32% in the past 14 days, which was higher than the 73.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.46, while its 200-day Moving Average is $17.03. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $18.61. Second resistance stands at $20.42. The third major resistance level sits at $21.46. If the price goes on to break the first support level at $15.76, it is likely to go to the next support level at $14.72. Should the price break the second support level, the third support level stands at $12.91.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
With a market capitalization of 1.49 billion, the company has a total of 88,805K Shares Outstanding. Currently, annual sales are 233,180 K while annual income is -321,550 K. The company’s previous quarter sales were 81,730 K while its latest quarter income was -41,230 K.
